The Assistant Secretary for Preparedness and Response (ASPR) and the Food and Drug Administration (FDA) within the US Department of Health and Human Services announced today that ASPR will resume distribution of bamlanivimab and etesevimab together and etesevimab alone (to pair with existing supplies of bamlanivimab at a facility for use under emergency use authorization 094) to all US states, territories, and jurisdictions.
Based on the FDA’s evaluation of the most recently available SARS-CoV-2 variant frequency data indicating increased prevalence of the Delta variant (B.1.617.2), ASPR is resuming distribution of bamlanivimab and etesevimab, which have been shown to be effective against the Delta variant when administered together.
The Delta variant is now the most dominant variant in the United States. Delta’s increase in prevalence has been associated with a concurrent decrease in the frequency of identified variants that are expected to be resistant to bamlanivimab and etesevimab.
The attached e-mail from ASPR details the above information.